Akeso, Inc. (9926.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$80.85 (-3.86%) as of
Key statistics
- Market cap
- 74.47B
- Forward P/E
- 55.63
- EPS (TTM)
- -1.140
- Dividend yield
- 0.00%
- 52-week range
- 79.550 – 156.000
- Beta
- -0.03
- Revenue (TTM)
- 3.45B
- Profit margin
- -28.03%
- Analyst target
- HK$154.16
- Volume
- 15.09M
About Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhongshan, China
- Employees
- 4,082
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.